Results 81 to 90 of about 411,149 (312)

Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings. [PDF]

open access: yes
Locally advanced esophageal cancer (LAEC) poses a significant and persistent challenge in terms of effective treatment. Traditionally, the primary strategy for managing LAEC has involved concurrent neoadjuvant chemoradiation followed by surgery. However,
Won Jin Jeon   +7 more
core   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy

open access: yes, 2020
Cancer is one of the leading causes of morbidity and mortality worldwide. Traditional treatments include surgery, chemotherapy and radiation therapy, and more recently targeted therapies including immunotherapy are becoming routine care for some cancers.
Katrin Campbell   +4 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Advances in immunotherapy for MMR proficient colorectal cancer.

open access: yes, 2023
Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect profile in various cancer types ...
Gerlinger, M   +3 more
core   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

open access: yesMolecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak   +10 more
wiley   +1 more source

Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5

open access: yesJournal of Translational Medicine
Background Nasopharyngeal carcinoma (NPC) is considered an immune-hot tumour. However, 30–80% of cases exhibit downregulation of antigen processing and presentation machinery (APM), enabling the evasion of host immunosurveillance.
Chai Phei Gan   +6 more
doaj   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Development of a technology for arranged electrofusion of mammalian cells : applicability in breast cancer immunotherapy

open access: yes, 2007
Schaper J. Development of a technology for arranged electrofusion of mammalian cells : applicability in breast cancer immunotherapy. Bielefeld (Germany): Bielefeld University; 2007.Cellular immunotherapy of cancer is a hot topic ever since the discovery ...
Schaper, J., Schaper, Janina
core  

Immunoadjuvants for cancer immunotherapy

open access: yes
In cancer immunotherapy host immunity is recruited to kill cancer cells; approved clinical use of checkpoint inhibitors, for most patients, only partially removed the inhibition of T-cell functions against tumors, systemic T-cell responses have not been ...
Carmona-Ribeiro, Ana Maria [UNESP]
core   +1 more source

Home - About - Disclaimer - Privacy